KNSA logo

KINIKSA PHARMACEUTICALS INTE

KNSANASDAQ
🏆 #1208 by market capEarnings Oct 26US Equity
$1,003.79▼ $49.59 (−4.94%)
Simulated price
🔔
Track KNSA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.9%
7d▲ 1219.4%
14d▲ 1195.5%
30d▲ 1177.1%
ytd▲ 2337.6%
1y▲ 2482.4%
🏦Market Cap
$5.77B
Small Cap
📈Revenue Growth (YoY)
+60.1%
High Growth
📊Gross Margin
54.5%
Healthy
💵FCF Margin
21.8%
Strong
⚖️P/S Ratio
6.9x
Fair
Otter Score
56
Weak

Trading Snapshot

Day Range
$998.76 – $1,016.44
52-Week Range
$35.20 – $82.94
Volume
$1.78B
Avg Volume
$2.05B
Shares Outstanding
76.2M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$678M
Last Q Revenue
$244M
P/E Ratio
70.8
P/S Ratio
6.9x
EPS (TTM)
$1.04
Dividend Yield
0.00%
Dilution (1yr)
+9.2%

Why Investors Own KNSA

  • ✓High-growth profile — revenue up +50.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 31% gross margin and 4% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KNSA logo

KINIKSA PHARMACEUTICALS INTE

KNSA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$678M▲ +60.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.6%▼ −36.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$77M▼ −269.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$25M▲ +0.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
79.0M▲ +9.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$156M▼ −$18M YoY
StockOtter · stockotter.space

About KINIKSA PHARMACEUTICALS INTE

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$1,334.24
▲ +32.9% Upside
High Target$1,499.66
Low Target$1,044.31
Based on 11 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

KINIKSA PHARMACEUTICALS INTE tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift KNSA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

KINIKSA PHARMACEUTICALS INTE announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.